GoJo makes commitment to antibiotic stewardship
AKRON, Ohio — GoJo pledged its commitment to antibiotic stewardship at the White House Forum on Tuesday. GoJo was among 150 companies at the White House Forum to announce commitments over the next five years to slow the emergence of antibiotic-resistant bacteria, detect resistant strains, preserve the efficacy of existing antibiotics and prevent the spread of resistant infections.
“A primary prevention approach to reduce the need for antibiotics is effective hand hygiene,” Joe Kanfer, chairman and CEO of GoJo, who is attending the Forum, said. “As we know, hand hygiene is one of the best measures you can take to prevent the spread of illness-causing germs. Staying healthy and preventing infections from happening is a very effective way to reduce the use of antibiotics. This is why practicing good hand hygiene — handwashing and hand sanitizing — is so important to overcoming the challenge of antibiotic resistance. We look forward to working with other organizations that share this dedication to improving public health.”
Last year, President Barack Obama signed an Executive Order launching Federal efforts to combat the rise in antibiotic-resistant bacteria. The Administration also issued its National Strategy on Combating Antibiotic-Resistant Bacteria, which outlines steps the U.S. government will take to improve prevention, detection and control of resistant pathogens. Earlier this year, the White House released its National Action Plan to Combat Antibiotic-Resistant Bacteria, an effort that identifies critical actions to be taken by government over the next five years. In addition, the President's FY 2016 Budget proposed nearly doubling the amount of Federal funding for combating and preventing antibiotic resistance to more than $1.2 billion.
Perrigo buys international OTC portfolio from GSK
DUBLIN — Perrigo on Tuesday acquired a portfolio of OTC brands from GlaxoSmithKline Consumer Healthcare, in connection with GSK's commitments to the European Commission and other regulators to divest these businesses because of its consumer health joint venture with Novartis.
Terms of the all-cash transaction were not disclosed.
Included in the deal are GSK's NiQuitin nicotine replacement therapy business, primarily in the European Economic Area and Brazil, and Novartis's legacy Australian NRT business, including the Nicotinell brand; several assorted OTC brands including Coldrex (cold and flu treatment) across the EEA, and Panodil (pain relief), Nezeril (nasal decongestant) and Nasin (nasal decongestant) in Sweden; and Novartis' legacy cold sore management products primarily in the EEA, marketed under the brand names Vectavir, Pencivir, Fenivir, Fenlips and Vectatone.
"This acquisition demonstrates Perrigo's ability to execute on our 'Base Plus Plus Plus' strategy, in which we make selective, accretive transactions to expand our durable base business," stated Joseph Papa, Perrigo president and CEO. "We are building on the global platform we established with the Omega Pharma acquisition to capture an even greater share of the $30 billion European OTC market opportunity with several well-established, complementary brands that bolster our OTC product portfolio. We are committed to making investments in these brands to grow their market positions in key geographies, by following Omega Pharma's proven approach to brand building."
"Perrigo is uniquely positioned to maximize the potential of these brands by leveraging Omega Pharma's leading European commercial infrastructure, pan-European distribution network, strong brand-building capabilities and exceptional management team. This announcement comes on the heels of our recent acquisition of European OTC dermatological product, Vitasil, which recently closed. With our global platform in place and our robust balance sheet, we are ideally positioned to execute immediately accretive deals, such as this one, that will have a multiplier effect on our growth."
The transaction has been unanimously approved by the boards of directors of Perrigo and GSK, and is expected to close in the third quarter of 2015, pending approval by the European Commission, the Australian Competition and Consumer Commission, and Brazil's Council for Economic Defense, as well as the satisfaction of customary closing conditions.
AmerisourceBergen strengthens distribution network, IT capabilities with new distribution centers
VALLEY FORGE, Pa. — AmerisourceBergen has announced plans to build three new distribution centers in Olive Branch, Miss., Shakopee, Minn. and Newburgh, N.Y. as part of an overall plan to continuously improve the wholesaler’s pharmaceutical supply chain delivery ability.
“We want to continue to get better at providing that customer experience every single day,” Bob Mauch, EVP and president AmerisourceBergen Drug, told Drug Store News. "One of the things that we’re really focused on here … is a patient-minded supply chain. We’re making these investments that make us even better at delivering that product every day on time to the right place.”
AmerisourceBergen is currently in the design stages of the three DCs, and Mauch said that by the time they’re completed, they will feature state-of-the-art automation and warehouse management systems. The new DCs will also feature advanced communication technologies.
“We’re investing in technology to be in even better contact with our customers in terms of deliveries and delivery times,” he said.
AmerisourceBergen has committed more than $1 billion over the last ten years into the distribution network and IT systems that handles nearly 35% of all of the pharmaceuticals sold and distributed throughout the country.
“We grow when our customers grow, so it’s no surprise that our goal is to help successfully execute the patient-focused strategies of the manufacturers, providers, pharmacists and retailers who we support,” Mauch said. “Enhancements to our distribution network combined with AmerisourceBergen’s unsurpassed knowledge and reach positions us to increase efficiency and drive innovation in pharmaceutical distribution and the delivery of healthcare.”
Construction on the new facilities is expected to start in the summer of 2015 and will take from 18-24 months to complete.
Loading Post Please Wait...